Abstract:Key PointsHistone deacetylase inhibitors are novel anticancer agents that induce tumour cell death, differentiation, and/or cell cycle arrest. As well as their intrinsic effects on tumour cells, histone deacetylase inhibitors may additionally affect neoplastic growth and survival by regulating host immune responses and tumour vasculature.The pleiotropic cellular effects of HDACi can act cooperatively to mediate potent anti-tumour activities; however, the molecular processes underlying these effects of HDACi remain to be fully elucidated.The activity of diverse non-histone proteins can be regulated by acetylation indicating that HDACi may have a much broader effect on cellular physiology than originally understood. Altered gene expression through the effects of HDACi on the activity of transcription factors and transcription-independent effects of HDACi are also important in their anticancer activities.In preclinical studies, several classes of HDACi have been found to have potent anticancer activities, and some have demonstrated promising therapeutic potential in early clinical trials for haematological malignancies such as cutaneous T-cell lymphoma, myelodysplastic syndromes and diffuse B-cell lymphoma.While HDACi show promise as single agent anticancer drugs, their use in combination with other agents may prove to be their most useful application. Already, HDACi have been shown to function synergistically with a host of structurally and functionally diverse chemical compounds and biologically active polypeptides.

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Histone deacetylases and cancer: causes and therapies

Histone Deacetylase Inhibitors as Anticancer Drugs

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

An Overview of HDAC Inhibitors and Their Synthetic Routes.

The Structure and Function of Histone Deacetylases: the Target for Anti-cancer Therapy

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

New Development of HDAC Inhibitors As Anti-Cancer Agents

Targeting histone deacetylases for cancer therapy: Trends and challenges

Anticancer activities of histone deacetylase inhibitors

The emerging roles of HDACs and their therapeutic implications in cancer

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Cyclic Peptide Histone Deacetylase Inhibitors

Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases

HDACs and their inhibitors in immunology: teaching anticancer drugs new tricks